Online inquiry

IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8234MR)

This product GTTS-WQ8234MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8234MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12472MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ5758MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ5665MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ15118MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ15226MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ15103MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ3014MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ10090MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA L19TNF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW